InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.26
(
-0.29%
)
US TECH 100
18,927.60
(
-0.06%
)
Dow Jones
41,503.10
(
-0.25%
)
Brent Oil
73.00
(
0.85%
)
Bitcoin
62,293.79
(
1.01%
)
Post# of 253151
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120462
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 180759

Monday, 07/28/2014 3:09:55 PM

Monday, July 28, 2014 3:09:55 PM

Post# of 253151
Addendum (from ABBV/ENTA standpoint): Inasmuch as GILD is apparently not seeking approval for an 8-week or shorter regimen of Sovaldi + GS-5816, there is no reason for GT1 patients, specifically, to prefer Sovaldi + GS-5816 to Sovaldi + Ledipasvir.

Thus, the Sovaldi + GS-5816 regimen does not present a competitive threat to ABBV/ENTA’s 3-DAA regimen, although it figures to compete with ABBV/ENTA’s pan-genotypic 2-DAA combination of ABT-493 + ABT-530.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up